QLF31907

N/A

Report date: 2025/04/07 15:07:41

Base Information

Drug NameQLF31907
Drug Alias NameQLF31907QLF-31907
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 9 agonists
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursCarcinoma, Transitional CellMelanoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Transitional CellMelanoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A